E&G Advisors’s Sarepta Therapeutics SRPT Stock Holding History

E&G Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,378	Closed	-$209K	–	184
2019 Q2	$209K	Buy	+1,378	New	+$167K	0.09%	172

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

E&G Advisors's SRPT Position: Q3 2019 in Review

E&G Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 1,378 shares — an estimated $209K sold.

E&G Advisors first reported a position in SRPT in Q2 2019 and held it in 1 quarter. The position peaked at $209K in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

E&G Advisors reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
E&G Advisors sold 1,378 Sarepta Therapeutics shares in Q3 2019, an estimated $209K.
E&G Advisors first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 1 quarter.
E&G Advisors's Sarepta Therapeutics position peaked at $209K in Q2 2019.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on E&G Advisors's 13F filing for Q3 2019, filed 10 Oct 2019.